Researchers report potential new treatment to stop Alzheimer's disease

Last March, researchers at UCLA reported the development of a molecular compound called CLR01 that prevented toxic proteins associated with Parkinson's disease from binding together and killing the brain's neurons.

Building on those findings, they have now turned their attention to Alzheimer's disease, which is thought to be caused by a similar toxic aggregation or clumping, but with different proteins, especially amyloid-beta and tau.

And what they've found is encouraging. Using the same compound, which they've dubbed a "molecular tweezer," in a living of Alzheimer's, the researchers demonstrated for the first time that the compound safely crossed the blood–brain barrier, cleared the existing amyloid-beta and tau aggregates, and also proved to be protective to the ' —another target of the disease—which allow cells to communicate with one another.

The report appears in the current online edition of the journal Brain.

"This is the first demonstration that molecular work in a mammalian ," said Gal Bitan, an associate professor of neurology at UCLA and the senior author of the study. "Importantly, no signs of toxicity were observed in the treated mice. The efficacy and toxicity results support the mechanism of this molecular tweezer and suggest these are promising compounds for developing disease-modifying therapies for Alzheimer's disease, Parkinson's and other disorders."

Molecular tweezers are complex capable of binding to other proteins. Shaped like the letter "C," these compounds wrap around chains of lysine, a basic amino acid that is a constituent of most proteins. Bitan and his colleagues, including Aida Attar, first author of the study and a graduate student in Bitan's lab, have been working with a particular molecular tweezer called CLR01.

In collaboration with scientists at the Università Cattolica in Rome, the researchers, working first in , found that CLR01 effectively inhibited a process known as synaptotoxicity, in which clumps of toxic amyloid damage or destroy a neuron's synapses.

Even though synapses in transgenic mice with Alzheimer's may shut down and the mice may lose their memory, upon treatment, they form new synapses and regain their learning and memory abilities.

"For humans, unfortunately, the situation is more problematic because the neurons gradually die in Alzheimer's disease," Bitan said. "That's why we must start treating as early as possible. The good news is that the molecular tweezers appear to have a high safety margin, so they may be suitable for prophylactic treatment starting long before the onset of the disease."

Next, using a radioactive "label," the researchers were able to confirm that the compound had crossed the mouse's blood–brain barrier and was effective in clearing the brain of amyloid-beta and tau aggregates.

"This work shows that molecular tweezers do a number of things—they help to ameliorate multiple pathologic features of Alzheimer's, including amyloid plaques, neurofibrillary tangles and brain inflammation, and our cell culture experiments demonstrated that molecular tweezers block the toxic effect of amyloid-beta on synaptic integrity and communication," Bitan said.

"We call these unique tweezers 'process-specific,' rather than the common protein-specific inhibitors," he added, meaning the compound only attacks the targeted toxic aggregates and not normal body processes. "That's a big deal, because it helps confirm evidence that the molecular tweezers can be used safely, ultimately supporting their development as a therapy for humans."

The next step, Bitan hopes, is to confirm that the tweezers improve memory and not just brain pathology. The researchers say they are working on this question and already have encouraging preliminary data.

Related Stories

Parkinson's disease stopped in animal model

Mar 02, 2012

(Medical Xpress) -- Millions of people suffer from Parkinson's disease, a disorder of the nervous system that affects movement and worsens over time. As the world's population ages, it's estimated that the number of people ...

Recommended for you

Putting dementia carers in control

11 hours ago

Experts will explore how improved support and powers for people caring for loved-ones with dementia can improve quality of life for both patients and carers around the UK.

Lilly, AstraZeneca team up on Alzheimer's drug

Sep 16, 2014

Eli Lilly and Co. plans to pay up to $500 million to fellow drugmaker AstraZeneca as part of a collaboration to develop and sell a potential Alzheimer's disease treatment that is in the early stages of clinical testing.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

wealthychef
5 / 5 (1) Nov 15, 2012
I am stunned at how many apparent cures for Alzheimers I've seen reported here and that there are zero actual treatments out there. I hope this one is ultimately successful...
Sinister1811
not rated yet Nov 16, 2012
I am stunned at how many apparent cures for Alzheimers I've seen reported here and that there are zero actual treatments out there. I hope this one is ultimately successful...


Yes, it's quite frustrating. I've also seen tonnes of treatments for various types of cancers reported here as well, but am not holding my breath for anything to happen in my lifetime.
Birger
5 / 5 (1) Nov 16, 2012
Medical research is frustrating.
The low-hanging fruit have been picked already by medical science and pharmacological companies, for each effective new medicine to be launched, a very large number fall by the wayside after a promising start.